The results of the Kaplan-Meier survival analysis indicated that ccRCC patients with a high level of GSDMB expression were associated with a poorer prognosis in comparison to patients with a low level of GSDMB expression in the following categories of various stages of cancer: T (T1 and T2, P = 0.014; T3 and T4, P = 0.008), N (N0, P = 0, N1; P = 0.405), M (M0, P = 0; M1, P = 0.028), and pathologic stage (I and II; P = 0.009; III and IV, P = 0.011) (Figure 5(a)). Here, GSDMB is linked to nonpapillary renal cell carcinoma.